B. Uitdehaag

Risk of fractures in patients with multiple sclerosis

C. Cooper, R. Herings, P. Vestergaard, 2012, Neurology.

CSF nitric oxide metabolites are associated with activity and progression of multiple sclerosis

F. Barkhof, C. Polman, B. Uitdehaag, 2004, Neurology.

Predicting clinical progression in multiple sclerosis after 6 and 12 years

M. Schoonheim, H. Vrenken, V. Popescu, 2019, European journal of neurology.

MR detection of multiple sclerosis lesions. transfer versus triple-dose gadolinium in the Single-dose gadolinium with magnetization

F. Barkhof, N. Silver, J. A. Castelijns, 1997 .

Disease course heterogeneity and OCT in multiple sclerosis

P Tewarie, J Killestein, A Petzold, 2014, Multiple sclerosis.

The utility of MRI in suspected MS: Report of the Therapeutics and Technology Assessment Subcommittee

F. Barkhof, C. Polman, B. Uitdehaag, 2004, Neurology.

Polymorphisms in the genes encoding interferon-gamma and interferon-gamma receptors in multiple sclerosis.

F. Barkhof, C. Polman, B. Uitdehaag, 2004, European journal of immunogenetics : official journal of the British Society for Histocompatibility and Immunogenetics.

Natalizumab drug holiday in multiple sclerosis: Poorly Tolerated

C. Polman, B. Uitdehaag, A. Seewann, 2010, Annals of neurology.

Association of interleukin-1β and interleukin-1 receptor antagonist genes with disease severity in MS

C. Polman, B. Uitdehaag, J. Crusius, 1999, Neurology.

Analysis of multiple candidate genes in association with phenotypes of multiple sclerosis

David Arteta, C. Polman, B. Uitdehaag, 2010, Multiple sclerosis.

High cumulative JC virus seroconversion rate during long‐term use of natalizumab

B. Uitdehaag, M. Wattjes, J. Killestein, 2016, European journal of neurology.